Tuesday, April 27, 2021 7:05:14 PM
Seems I saw a silver lining when comparing NWBO with other innovative stocks investment I have such as QS, AMRS, RMO etc. What I saw is no matter how good the sciences are or no matter how relevant their products are to market demand if the companies are not near in their production stages then the stocks price would undoubtedly being tested multiple times. We could see the stock prices being cut 75% from its high. Yikes!
Luckily I didn't do anything stupid when NWBO stock price was pounded from 35 cents to 19 cents in 2019 and again from 21 cents to 14 cents in 2020.
Based on this experience the best time to buy NWBO stock was actually when the price reached around that pivot point 15 cents or 16 cents.
Hoping the next investing in other baby biotech, we all don't have to endure so much unnecessary painful experiences.
Instead we all can take advantage of it when the opportunities are presented by shorts near enough to the TLD announcement.
Fear of missing out is the enemy of Longs.
Just personal opinions.
Luckily I didn't do anything stupid when NWBO stock price was pounded from 35 cents to 19 cents in 2019 and again from 21 cents to 14 cents in 2020.
Based on this experience the best time to buy NWBO stock was actually when the price reached around that pivot point 15 cents or 16 cents.
Hoping the next investing in other baby biotech, we all don't have to endure so much unnecessary painful experiences.
Instead we all can take advantage of it when the opportunities are presented by shorts near enough to the TLD announcement.
Fear of missing out is the enemy of Longs.
Just personal opinions.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
